IFNA1 and melanoma: Baseline high IFN signature is associated with similar responses and EFS for ICI-monotherapies and ICI-doublets while only the nivolumab/ipilimumab combination can restore the immunotherapy response in melanoma patients with low IFN signature (85, 86).